"Ozempic face": what the evidence shows about facial changes on GLP-1 medicines

"Ozempic face": what the evidence shows about facial changes on GLP-1 medicines

Quick answer. "Ozempic face" is a popular name for facial hollowing, loose skin and deeper folds that some people notice after losing a lot of weight on a GLP-1 medicine. It is not a diagnosis, and the label sections the Atlas read do not mention it. A 2026 review says similar changes follow other substantial weight loss, so the name may wrongly suggest an effect of the drug itself. A small imaging series measured midface volume loss, but the Atlas found no controlled study showing that GLP-1 medicines change the face more than the same weight loss by other means. The evidence for treatments is small and uncontrolled.

What the term means

Ozempic is a brand of semaglutide approved for type 2 diabetes, and the nickname spread to weight-loss medicines in general. A 2026 dermatology review describes it as the look of accelerated facial aging, with volume loss, loose skin and less structural support. A 2026 review in Aesthetic Surgery Journal notes that the term can imply a drug-specific adverse effect, although similar changes occur after other forms of substantial weight loss. A 2026 systematic review says the changes are not recognized as a distinct clinical entity and may overlap with those after other rapid or massive weight loss.

What has been measured

StudyWhat it didWhat it foundWhat to know
Serial imaging of 20 patients, as summarized in Yoo's 2026 reviewMeasured midface volume on imaging over time in people on GLP-1 medicinesA median 9% reduction in midfacial volume, with more loss in the superficial fat compartments than the deep ones (11% versus 7%). A regression estimated about 7% midfacial volume loss per 10 kg lost.Small, with no comparison group, and reported through a review. The estimate ties volume loss to kilograms lost. It does not separate the drug from the weight loss.
Survey of 1,226 participants, as summarized in the same reviewAsked people about facial changesMore reports of facial volume loss and loose skin with greater percentage weight loss.Self-reported by people who chose to answer.
Studies after weight-loss surgery, as summarized in the same reviewLooked at faces after bariatric surgeryFacial deflation and a more aged look, particularly in older patients and after larger losses.Shows that similar changes happen without a GLP-1 medicine.
Firsowicz and colleagues, Dermatologic Surgery, 2026Abdominal fat biopsy samples (10 in all), comparing patients on GLP-1 medicines with untreated controlsFewer fat-derived stem cells in the GLP-1 group, about four-fold fewer (11.0 versus 44.8 cells per square millimeter).A small laboratory study of belly fat, not the face. The authors propose it as a possible mechanism beyond weight loss. It does not show what happens in facial tissue.
Barone and colleagues, Aesthetic Plastic Surgery, 2026A literature review of 40 studies of skin changes with GLP-1 medicines, including trials, observational studies and case reportsReported facial volume loss, thinner skin, loss of collagen and elastin and lower elasticity. It names older age, a long history of obesity, rapid weight loss, poor hydration and low protein intake as risk factors for worse outcomes.A literature review, so the risk factors come from the studies it pooled. Another 2026 review says the independent effect of weight-loss speed is still uncertain.

Is it the drug or the weight loss?

The studies the Atlas found cannot separate the two. The 2026 review by Yoo concludes that current evidence favors deflation from weight loss on top of a person's baseline anatomy and aging. It says the independent effect of how fast weight comes off, and the roles of menopause and hormone therapy, remain uncertain.

A drug effect on fat tissue beyond weight loss has been proposed, and the small stem-cell study above is one piece of that idea. It is unproven. The Atlas found no controlled study that compared facial change after the same weight loss with a GLP-1 medicine and with another method.

What the labels say

In the parts of the Wegovy and Zepbound labels the Atlas read, which include the warnings and adverse reactions sections, the terms facial, sagging, laxity and wrinkle do not appear. Some later sections were not read, so check the current labels. Both labels list hair loss as a common adverse reaction and say hair loss reactions were associated with weight reduction. The hair loss page has the rates.

Treatments that have been studied

Reviews say evidence on treating these changes is limited and largely uncontrolled. The Atlas does not recommend any treatment.

StudyWho or whatWhat it foundWhat to know
Maglitto and colleagues, Aesthetic Plastic Surgery, 2026 (systematic review)Four uncontrolled observational studies with 98 treated participants, testing injectable biostimulators and fillers, radiofrequency and a topical productAll four reported favorable results within the treated group.No comparison groups, and the populations, treatments and follow-up differed. Two of the four studies included people whose weight loss had other causes. The authors say this prevents conclusions about effectiveness and that the evidence is preliminary and insufficient to support a validated treatment algorithm.
Avelar and colleagues, Clinical, Cosmetic and Investigational Dermatology, 202615 women aged 30 to 50 in four Latin American countries who had lost about 18% of their weight and were treated with two kinds of fillerAt about 90 days, laxity and wrinkle scores improved and 87% were satisfied or very satisfied. No serious adverse events were reported, and bruising and swelling cleared within 72 hours.A retrospective case series with no control group. Three of the authors work for Galderma, a maker of fillers.
Rahman and colleagues, Aesthetic Plastic Surgery, 202612,000 simulated faces (digital twins) randomized to injectable treatments in softwareIn the simulation, every preventive injectable reduced sagging compared with control.Not a trial in people. The title says trial and the journal tags it as randomized, but nobody was treated, and the result is the output of a computer model.

What people report

In online communities, people commonly describe noticing a more tired or older look as weight comes off, comparing before and after photos, and asking whether skin treatments or fillers help. None of this was measured. People who are worried are more likely to post, and the posts cannot say whether the medicine, the amount of weight lost or the speed of loss is the cause.

Quick answers

What is Ozempic face?
A nickname for facial hollowing, loose skin and deeper folds that some people notice after substantial weight loss on a GLP-1 medicine. It is not a diagnosis.
Is Ozempic face a real side effect?
Reviews say facial volume loss and loose skin are reported during weight loss on these medicines. The label sections the Atlas read do not list them, and similar changes follow other substantial weight loss.
Is it caused by the medicine or by the weight loss?
The evidence favors weight loss on top of a person's baseline anatomy and aging. A separate effect of the drug has been proposed but not shown, and the effect of how fast weight comes off is uncertain.
How much facial volume is lost?
In one imaging series of 20 patients, the median was 9% of midfacial volume, and a regression estimated about 7% per 10 kg lost. These are small, uncontrolled data.
Does it happen with Wegovy and Zepbound as well as Ozempic?
The nickname refers to semaglutide, but the studies group GLP-1 receptor agonists. The Atlas found no study that compared facial change between medicines.
Can it be prevented?
The Atlas found no controlled study showing a way to prevent it. One study of injectable prevention used a computer simulation of 12,000 digital faces, not people, and the framework in a 2026 systematic review is described by its authors as hypothesis-generating.
Do fillers or other treatments help?
Small uncontrolled studies report improvement. A 2026 systematic review found four such studies with 98 treated people and said the evidence cannot support conclusions about effectiveness.
Do protein and fluids matter?
A 2026 literature review lists poor hydration and low protein intake among risk factors for worse skin outcomes. The Atlas found no controlled study showing that raising either prevents facial change. The protein page covers what is known about protein and muscle.

Questions to ask

  • How fast am I losing weight, and does that matter for my skin or face?
  • If my face looks different, how do we tell weight loss from something else?
  • If I am thinking about an aesthetic treatment, who is qualified, and what does the evidence say about it?
  • Could protein, strength training or hydration matter for my skin and muscle?
  • Does anything about my other medicines or health change the answer?

What is still unknown

  • The Atlas found no controlled study showing that GLP-1 medicines change the face more than the same weight loss by other means.
  • Whether the speed of weight loss has an effect of its own is uncertain, according to a 2026 review.
  • The imaging data come from small series. The Atlas found no large study that measured facial change before and after treatment.
  • The Atlas found no controlled study of a treatment for these changes. The treatment studies are uncontrolled, small or computer simulations.
  • Whether the changes reverse after stopping the medicine or regaining weight is not described in the sources the Atlas read.
  • How common the changes are is not established. The surveys are self-reported.

Back to getting started

Sources

  1. Glucagon-like peptide-1 receptor agonist-associated facial changes: a comprehensive review of pathophysiology, clinical manifestations, risk factors, prevention, and management Yoo KH. Aesthet Surg J. 2026 (published online October 14, 2026). PMID 42872378. Funding: Not stated in the abstract. Journal article
  2. Beyond weight loss: facial remodeling associated with GLP-1 receptor agonists, a systematic review and therapeutic framework Maglitto F, et al. Aesthetic Plast Surg. 2026 (published online October 12, 2026). PMID 42864543. Funding: Not stated in the abstract. Journal article
  3. "Ozempic face" and facial aging Fathizadeh S, et al. Clin Dermatol. 2026 (published online October 10, 2026). PMID 42858788. Funding: Not stated in the abstract. Journal article
  4. Cutaneous variations in stem-cell population in those on GLP-1 receptor agonists: a comparative controlled study Firsowicz M, et al. Dermatol Surg. 2026;52(6S):S39-S44. PMID 42210886. Funding: Not stated in the abstract. Journal article
  5. Aesthetic use of poly-L-lactic acid and hyaluronic acid fillers in medication-driven weight loss due to GLP-1 receptor agonists: real-world case series from Latin America Avelar LET, et al. Clin Cosmet Investig Dermatol. 2026;19:620566. PMID 42328491. Funding: Not stated in the abstract. Journal article
  6. Computational trial of prophylactic biostimulator interventions to mitigate facial sagging associated with GLP-1 receptor agonist induced weight loss Rahman E, et al. Aesthetic Plast Surg. 2026;50(18):7703-7731. PMID 42414642. Funding: See the disclosures in the article. Journal article
  7. Effects of GLP-1 receptor agonists on skin quality: a comprehensive literature review Barone M, et al. Aesthetic Plast Surg. 2026;50(13):5403-5407. PMID 42162206. Funding: Not stated in the abstract. Journal article
  8. Wegovy (semaglutide) injection and tablets: prescribing information Novo Nordisk, on DailyMed (U.S. National Library of Medicine). Label version 6/2026. One label covers both the injection and the tablets. Official FDA label on DailyMed
  9. Zepbound (tirzepatide) injection: prescribing information Eli Lilly and Company, on DailyMed (U.S. National Library of Medicine). Label version 8/2026. Official FDA label on DailyMed